Search Results - "Wong, Chiung Ing"

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies by WONG, Chiung-Ing, KOH, Tong-San, LIM, Robert, SUKRI, Norita, LIM, Siew-Eng, ONG, Ai-Bee, STEINBERG, Joyce, GUPTA, Neeraj, PRADHAN, Rajendra, HUMERICKHOUSE, Rod, GOH, Boon-Cher, SOO, Ross, HARTONO, Septian, THNG, Choon-Hua, MCKEEGAN, Evelyn, YONG, Wei-Peng, CHEN, Chien-Shing, LEE, Soo-Chin, WONG, John

“…To determine the safety and tolerability of ABT-869 at escalating doses and its effects on biomarkers relevant for antiangiogenic activity in patients with…”
Get full text

Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients by Xiang, Xiaoqiang, Rao Jada, Srinivasa, Hua Li, Hui, Fan, Lu, San Tham, Lai, Ing Wong, Chiung, Chin Lee, Soo, Lim, Robert, Yu Zhou, Qing, Cher Goh, Boon, Huat Tan, Eng, Chowbay, Balram

“…OBJECTIVETo investigate the pharmacogenetic effect of SLCO1B1 *1a, *1b, *5 and *15 polymorphisms on irinotecan disposition in Asian cancer patients…”
Get full text

Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma by Wong, Chiung-Ing, Yap, Hui-Ling, Lim, Seng-Gee, Guo, Jia-Yi, Goh, Boon-Cher, Lee, Soo-Chin

“…Aim:  Small molecules targeting the epidermal growth factor receptor (EGFR) intracellular tyrosine kinase domain have shown promising activity in cancer…”
Get full text

Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients by Jada, Srinivasa Rao, Lim, Robert, Wong, Chiung Ing, Shu, Xiaochen, Lee, Soo Chin, Zhou, Qingyu, Goh, Boon Cher, Chowbay, Balram

“…The objectives of the present study were (i) to study the pharmacogenetics of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A in three distinct healthy Asian…”
Get full text

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity by Fan, Lu, Goh, Boon-Cher, Wong, Chiung-Ing, Sukri, Norita, Lim, Siew-Eng, Tan, Sing-Huang, Guo, Jia-Yi, Lim, Robert, Yap, Hui-Ling, Khoo, Yok-Moi, Iau, Philip, Lee, How-Sung, Lee, Soo-Chin

“…OBJECTIVESDoxorubicin is a cytotoxic drug with potential for severe myelosuppression that is highly variable and poorly predictable. METHODSWe correlated CBR1…”
Get full text

Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes by Chan, Daniel, Yeo, Wee-Lee, Tiemsim Cordero, Maricel, Wong, Chiung-Ing, Chuah, Benjamin, Soo, Ross, Tan, Sing-Huang, Lim, Siew-Eng, Goh, Boon-Cher, Lee, Soo-Chin

“…Summary Background Patients with metastatic breast cancer (MBC) are usually exposed to both anthracyclines and taxanes during neoadjuvant or adjuvant treatment…”
Get full text

Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer by Lee, Soo-Chin, Xu, Xin, Chng, Wee-Joo, Watson, Mark, Lim, Yi-Wan, Wong, Chiung-Ing, Iau, Philip, Sukri, Norita, Lim, Siew-Eng, Yap, Hui-Ling, Buhari, Shaik Ahmad, Tan, Patrick, Guo, Jiayi, Chuah, Benjamin, McLeod, Howard L, Goh, Boon-Cher

“…OBJECTIVETumor gene expression signatures have been used to classify, prognosticate, and predict chemotherapy sensitivity in breast cancer, although almost all…”
Get full text

Ophthalmoplegia in a patient with breast cancer by Ng, Esther S T, Tan, Sing-Huang, Ling, Winnie H Y, Venkatesh, Sudhakar K, Wong, Chiung-Ing

Get more information

A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers by Yong, Wei-Peng, Wang, Ling-Zhi, Tham, Lai-San, Wong, Chiung-Ing, Lee, Soo-Chin, Soo, Ross, Sukri, Norita, Lee, How-Sung, Goh, Boon-Cher

“…Purpose The aims were to determine the maximum tolerable dose (MTD) of docetaxel with CYP3A inhibition by ketoconazole, and to correlate the pharmacokinetics…”
Get full text